이번주 생명과학과 열린세미나 연사님은 성균관대학교 글로벌바이오메디컬공학과 박천권 교수님입니다.
사회적 거리두기 4단계 연장에 따라 3주차 세미나는 사전제작되었습니다. 오늘부터 열람 가능합니다.
세미나 영상 열람을 희망하는 학생은 아래 구글 설문지에 응답해주시면 세미나 교과목(고급생명과학세미나2) 청강권한을 부여해드리겠습니다.
박천권 교수님은 2018년 글로벌바이오메디컬공학과에 부임하셔서 융합생체재료공정 연구실(http://cbrl.skku.edu/)을 운영하고 계십니다. 면역치료, 약물전달, 생체재료 등을 연구하고 계셔서 우리 학과에도 비슷한 분야에 관심을 갖고 있는 학생들이 있으리라 생각합니다. 이번 세미나에서는 암의 면역치료에 대해 기초부터 쉽게 설명해주실 예정입니다. 사전제작 영상으로 세미나를 듣다보니 교수님께 직접 질문하는 시간이 없어 아쉽지만, 질문이 있는 학생은 교수님께 직접 메일(firstname.lastname@example.org)을 보내도 되고, 아이캠퍼스 질문답변란에 질문을 남기면 담당교수가 전달할 수도 있습니다. 아래 교수님 소개와 강연 초록을 참고하기 바랍니다.
Chun Gwon Park is an Assistant Professor in the Department of Biomedical Engineering at Sungkyunkwan University, Korea. He received his B.S. (2009) from Hanyang University and his Ph.D. (2014) from Seoul National University under the supervision of Prof. Young Bin Choy in the Department of Biomedical Engineering. Then, Dr. Park worked as a research fellow at Harvard Medical School and Dana-Farber Cancer Institute, where he focused on biomaterials-based cancer immunotherapy until he became a faculty member at Sungkyunkwan University in 2018. His research is mainly focused on developing innovative biomaterials-based drug delivery approaches to increase the efficacy and decrease the toxicity of clinically available therapies including cancer immunotherapy. Dr. Park has published > 50 peer-reviewed research papers including Science Translational Medicine, Nature Communications, Science, Advanced Science and Biomaterials. Dr. Park was awarded domestically- or/and internationally-recognized Awards including Outstanding Young Scientist Award from the Korean Society for Biomaterials, Korea (2021).
Enhancing Cancer Immunotherapy using Biomaterials
Unlike traditional approaches in oncology, cancer immunotherapy harnesses a patient’s coordinated and adaptive immune system in order to combat the disease. Recent clinical data have supported the utility of this therapeutic modality. The benefits of cancer immunotherapy include the potential 1) to treat all types of cancer, regardless of the underlying mutations or cell of origin; 2) to prevent metastasis and relapse by generating memory antitumor immunity; and 3) to decrease side effects relative to conventional cytotoxic treatment approaches (e.g., chemotherapy and radiotherapy). Still, the therapeutic index of cancer immunotherapy must be improved, since the proportion of patients responding to this approach remains unsatisfactory and the therapy often causes systemic toxicity following parental administration. To address these issues, we used various biomaterials-based drug delivery approaches to deliver immunomodulatory compounds in a spatiotemporally controlled manner in order to improve their efficacy and safety relative to conventional systemic administration.
In one example, we designed and prepared a hydrogel loaded with a combination of immunomodulatory drugs. We showed that a majority of mice were cured after administration of the hydrogel, which sustained the release of the immunotherapy. In contrast, most mice succumbed to tumor recurrence and metastasis following systemic or local administration of the same therapeutic combination in solution. In a second example, we developed antibody-targeted nanoparticles to target the delivery of immunomodulatory small molecules to specific endogenous immune cell subsets, including PD-1-expressing cells, in order to improve the efficacy and safety of the drug. We showed that the nanoparticles could specifically bind to the targeted cells in blood as well as tumors. Targeted delivery of the drug delayed tumor growth and extended the survival of tumor-bearing mice.
Our findings suggest that properly designed biomaterials and drug delivery technologies are useful tools to ensure sustained and/or targeted delivery of immunomodulatory compounds. Spatiotemporal control of drug release can harness the full potential of cancer immunotherapy, improving its efficacy while minimizing its toxicity by concentrating the action of such compounds on the relevant cells.